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0022-2836 © 2010 Elsevier Ltd. Open accWe report the first crystal structures of a penicillin-binding protein (PBP),
PBP3, from Pseudomonas aeruginosa in native form and covalently linked to
two important β-lactam antibiotics, carbenicillin and ceftazidime. Overall,
the structures of apo and acyl complexes are very similar; however,
variations in the orientation of the amino-terminal membrane-proximal
domain relative to that of the carboxy-terminal transpeptidase domain
indicate interdomain flexibility. Binding of either carbenicillin or ceftazi-
dime to purified PBP3 increases the thermostability of the enzyme
significantly and is associated with local conformational changes, which
lead to a narrowing of the substrate-binding cleft. The orientations of the
two β-lactams in the active site and the key interactions formed between the
ligands and PBP3 are similar despite differences in the two drugs, indicating
a degree of flexibility in the binding site. The conserved binding mode of
β-lactam-based inhibitors appears to extend to other PBPs, as suggested by
a comparison of the PBP3/ceftazidime complex and the Escherichia coli
PBP1b/ceftoxamine complex. Since P. aeruginosa is an important human
pathogen, the structural data reveal the mode of action of the frontline
antibiotic ceftazidime at the molecular level. Improved drugs to combat
infections by P. aeruginosa and related Gram-negative bacteria are sought
and our study provides templates to assist that process and allows us to
discuss new ways of inhibiting PBPs.© 2010 Elsevier Ltd. Open access under CC BY license.resses: raymond.owens@rc-harwell.ac.uk; ren@strubi.ox.ac.uk.
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The bacterial cell wall consists of N-acetylgluco-
samine-N-acetyl muramic polymers cross-linked via
the penultimate D-alanine residues of muramyl
pentapeptides to form a peptidoglycan network
that is essential for normal cell survival. Penicillin-
binding proteins (PBPs) are membrane-bound
enzymes involved in the final stages of bacterial
cell wall synthesis on the periplasmic side of the
membrane. They have been classified into a high-
molecular-mass (HMM) group, members of which
are essential for cell viability, and a low-molecular-
mass (LMM) group, members of which appear
dispensable for normal cell growth.1 HMM PBPs
are further divided into class A enzymes, which
catalyze both the polymerization of a peptidoglycan
from disaccharide peptides (glycosyltransferase)
and the cross-linking of muramyl peptides (trans-
peptidase), and class B enzymes, which only possess
transpeptidase activity. HMM PBPs consist of two
domains: an N-terminal membrane-proximal do-
main and a C-terminal domain harboring transpep-
tidase activity. In the case of class A PBPs, the N-
terminal domain contains glycosyltransferase activ-
ity; the function of the equivalent domain in class B
PBPs is not known. The smaller LMM PBPs are D,D-
carboxypeptidases that remove the terminal D-
alanine from the muramyl peptide, thus controlling
the level of peptidoglycan cross-linking.1 As the
name indicates, PBPs are also the primary targets of
β-lactam antibiotics, which act as suicide substrates
by mimicking the D-alanyl-D-alanine stem peptide of
peptidoglycan precursors. β-Lactams block the
activity of transpeptidases and carboxypeptidases
by acylating the active site serine residue.2
Crystal structures have been reported for HMM
PBPs from the Gram-negative Escherichia coli
(PBP1b)3 and Neisseria gonorrhoeae (PBP2),4 and the
Gram-positive Streptococcus pneumoniae (PBP1b,5
PBP2x,6–10 and PBP2b11) and Staphylococcus aureus
(PBP2a12), including both apo-enzymes and com-
plexes with β-lactams. All of these structures show
similar active sites, featuring three conserved
catalytic motifs in the transpeptidase domain. The
β-lactams are covalently bound to the active site
serine via the carbonyl of the opened cyclic amide.
Resistance to β-lactams can be rationalized to some
extent by examining the structures of PBPs from
resistant bacteria, which have mutations in residues
close to the catalytic motifs.2,7,11
Our interest is primarilyPseudomonas aeruginosa, an
opportunistic pathogen that is responsible for severe
life-threatening infections, especially in patients
suffering from chronic respiratory diseases such as
cystic fibrosis.13 The genome of P. aeruginosa strain
PAO114 encodes fourHMMPBPs, including one class
A enzyme (PBP1a) and three class B enzymes (PBP2,
PBP3, and PBP3a), which are orthologues of thecorresponding enzymes in E. coli. PBP3 shares 42%
sequence identity with the corresponding protein in
E. coli and has been identified as the primary target of
a number of β-lactams used to treat pseudomonal
infections, including the cephalosporin analogues
cefsulodin15 and ceftazidime,16 piperacillin,17 and the
parenteral carbapenem, doripenem.18
Compared to many other Gram-negative bacteria,
P. aeruginosa is highly resistant to antibiotics and, as
with many bacterial pathogens, resistance increases
with repeated use and misuse of antibiotics. As is
typical of Gram-negative bacteria, antibiotic resis-
tance in P. aeruginosa is largely due to a combination
of β-lactamase production and the action of numer-
ous efflux pumps.19 However, treatment with high
doses of piperacillin has been shown to be associ-
ated with reduced binding to PBPs in clinical
isolates of P. aeruginosa.17 In laboratory strains
lacking β-lactamases, the overproduction of PBP3
in P. aeruginosa promotes reduced sensitivity to
cefsulodin;20 in a separate study, increased resis-
tance to cefsulodin was observed to be associated
with reduced binding to endogenous PBP3.15
PBP3 is a therapeutic target in P. aeruginosa, and we
have determined structures of this HMM PBP in its
native form and in complex with two relevant drugs,
carbenicillin and ceftazidime (Supplementary Mate-
rial, Fig. S1). Carbenicillin is a broad-spectrum
semisynthetic penicillin derivative and was one of
the first derivatives to display significant activity
against Pseudomonas.21 The aminothiazolyl-carrying
ceftazidime16 is similar to cefotaxime, the first third-
generation cephalosporin to be marketed, but differs
with a 2-carboxy-2-oxypropaneiminogroup replacing
a methoxy amino group. This difference increases
efficacy against P. aeruginosa, making ceftazidime one
of only a handful of drugs currently used to treat
Pseudomonas infections. Ceftazidime also displays
potent activity against another of the so-called
superbugs, Burkholderia pseudomallei, which was
previously known as Pseudomonas pseudomallei and
is the causal agent ofmelioidosis, a serious infection in
humans found mainly in Asia. Indeed, ceftazidime is
the frontline drug for the treatment of this disease.
We describe the crystal structures of apo-PBP3
and the acyl complexes with carbenicillin and
ceftazidime, as well as the similarities and differ-
ences between the three structures, and discuss
structural features that might be exploited to derive
novel inhibitors of therapeutic value.
Results and Discussion
Production of PBP3 and binding to β-lactams
A soluble version of recombinant P. aeruginosa
PBP3 was produced by truncating the sequence at
the N-terminus by 34 residues to remove the
Fig. 1. Thermal shift assay. (a) PBP3 screened with 500 μM carbenicillin, giving aΔTm of +13.2 °C. The blue curve is the
native protein, and the red curve is the complex. (b) PBP3 screened with 500 μM ceftazidime, giving a ΔTm of +14.5 °C.
The blue curve is the native protein, and the black curve is the complex.
175Native and Antibiotic-Bound P. aeruginosa PBP3predicted transmembrane helix. The molecular mass
of the purified protein determined by size-exclusion
chromatography was approximately 54 kDa com-
pared to a calculated value of 61 kDa, indicating that
it is most likely a monomer in solution. Binding of
carbenicillin and ceftazidime to the recombinant
protein was confirmed using a thermal shift assay.
The assay used a real-time PCR machine to detect
changes in fluorescence during the thermal un-
folding of the protein in the presence of SYPRO
Orange. Significant temperature stabilization of the
protein was observed for both compounds, with
shifts in the midpoint transition temperature (ΔTm)
of 13.2±0.2 °C and 14.5±0.1 °C following incubation
with either 0.5 mM carbenicillin or 0.5 mM ceftazi-
dime, respectively (Fig. 1).
Overall structure
Three isomorphous structures of P. aeruginosa
PBP3 have been determined: apo-PBP3 at 2.0 Å
resolution, PBP3/carbenicillin complex at 2.4 Åresolution, and PBP3/ceftazidime complex at 2.6 Å
resolution. The PBP3/carbenicillin complex was
derived from a sample obtained by cocrystallization,
and the ceftazidime complex was derived by
soaking a native crystal in mother liquor containing
the antibiotic. The initial structure was determined
using the coordinates of PBP2 from N. gonorrhoeae4
as molecular replacement model [Protein Data
Bank (PDB) code 3equ]. Crystallographic statistics
(Table 1) indicate that acceptable models have
resulted from the analyses. In all three structures,
residues 35–49, 492–497, and 560–577 are dis-
ordered and do not have sufficient electron density
to allow reliable model building.
PBP3 is a two-domain protein comprising a
C-terminal transpeptidase linked to an extended
N-terminal domain. Overall, PBP3 resembles
other class B PBPs, although it lacks the additional
C-terminal domain unique to the PBP2x structure
(Fig. 2). In common with these other class B PBPs,
there is an α-helical subdomain or “head” domain11
(residues 80–149) towards the N-terminus, which
Table 1. X-ray data collection and refinement statistics
Data collection
X-ray source Diamond I04 ESRF ID23-2 Diamond I02
Data set PBP3 native PBP3/carbenicillin PBP3/ceftazidime
Wavelength (Å) 1.0000 0.8726 0.9750
Space group P212121 P212121 P212121
Unit cell parameters a, b, c (Å) 66.76, 81.51, 85.94 69.48, 83.44, 89.85 67.08, 81.81, 87.79
Resolution range (Å) 30.0–2.00 (2.07–2.00) 30.0–2.40 (2.49–2.40) 30.0–2.60 (2.69–2.60)
Unique reflections 32,803 (3150) 21,168 (2081) 15,047 (1331)
Completeness (%) 99.6 (96.7) 99.6 (99.9) 98.6 (89.3)
Redundancy 10.4 (5.7) 5.4 (4.9) 5.6 (3.7)
〈I/σ(I)〉 23.9 (3.0) 8.6 (1.9) 11.9 (2.5)
Rmerge 0.143 (0.575) 0.172 (0.582) 0.166 (0.545)
Refinement statistics
Resolution range (Å) 30.0–2.00 30.0–2.40 30.0–2.60
Number of reflections (working/test) 31,100/1649 19,881/1090 14,178/764
R-factora (Rwork/Rfree) 0.171/0.213 0.195/0.242 0.207/0.267
Number of atoms (protein/other) 3787/220 3801/158 3841/69
RMSD on bond lengths (Å) 0.007 0.007 0.006
RMSD on bond angles (°) 1.1 1.1 1.0
Mean B-factor (protein/other) (Å2) 32/38 30/33 21/16
Ramachandran plot
Residues in preferred regions (%) 469 (95.7) 474 (96.9) 373 (88.2)
Residues in allowed regions (%) 21 (4.3) 14 (2.9) 46 (10.9)
Residues in disallowed regions (%) 0 (0.0) 1 (0.2) 1 (0.2)
a Rwork and Rfree are defined by R=∑hkl‖Fobs|−|Fcalc‖/∑hkl|Fobs|, where hkl are the indices of the reflections (used in refinement for
Rwork; 5%, not used in refinement, for Rfree), and Fobs and Fcalc are the structure factors deduced frommeasured intensities and calculated
from the model, respectively.
176 Native and Antibiotic-Bound P. aeruginosa PBP3was not resolved in the PBP2 structure (Fig. 2 and
Table 2). The function of the N-terminal domain of
class B PBPs is not known but possibly serves to
position the transpeptidase domain away from the
inner membrane as part of a multienzyme complex
involved in cell wall biosynthesis.24
Despite a relatively low sequence identity, the
fold of the transpeptidase domain is highly con-
served among PBPs. For the class B enzymes, the
RMSD for the overlap of approximately 80% of the
Cα atoms is 1.5–2.0 Å, depending on the structure
(Table 2). The structural superimpositions also
revealed that the orientation of the transpeptidase
domains varied with respect to the N-terminal
domains in the different structures. For example, in
the overlay of the PBP3 and PBP2b transpeptidase
domains, the N-terminal domains of the PBPs were
rotated as rigid bodies by about 24° with respect to
each other (Table 2), indicating considerable rota-
tional freedom between the N-terminal domain and
the C-terminal domain.
Active site structure
The active site of PBP3 is located in a long cleft
running parallel with the β3 strand across the lower
part of the transpeptidase domain. The three
conserved structural motifs that are common to D,
D-peptidases and β-lactamases are found here and
have well-defined electron density (Fig. 3a). The
SXXK motif (S294-T295-V296-K297) is located at the
N-terminal end of α2 and includes the nucleophilicS294, together with the α8–β2f loop (residues 407–
409) that forms the base of the cleft. The SXN motif
(S349-S350-N351) occurs in the α4–α5 turn, and
residues 328–334 (β2c and β2c–β2d loop) form one
side of the elongated cleft; the third motif KS/TG
(K484-S485-G486) is positioned on strand β3 and,
together with residues 530–533 in the β5–α11 loop,
forms the opposite side of the cleft. Unlike in
PBP2a,12 which is relatively resistant to β-lactam
inhibition, the catalytic S294 is positioned favorably
for acylation in an open substrate-binding pocket.
The three conserved structural motifs interact with
each other via a network of hydrogen bonds: the
hydroxyl group of S294 forms hydrogen bonds with
the side chains of both K297 and K484 (2.7 Å and
2.8 Å), which are hydrogen bonded to S349 and
N351, respectively (Fig. 3d). The position of K297
makes it one of the possible proton receptors from
the catalytic S294 during the acylation reaction, in
addition to the possible contribution of the β-lactam
carboxylate. There are eight water molecules in the
active site cleft of apo-PBP3, which form an
extensive hydrogen-bonding network with the
protein. The two loops connecting β3 and β4
(K490-A500) and β5 and α11 (S526-F531) are
disordered in the apo-enzyme.
Comparison of apo-enzyme and
acyl-enzyme complexes
In comparing the apo-PBP3 and acyl-PBP3 com-
plexes, it is apparent that the N-terminal domains
Fig. 2. The overall structure of PBP3. (a) A ribbon diagram of the PBP3/carbenicillin complex showing the overall
fold, antibiotic binding site, and bound glycerol. The diagram is rainbow-colored from blue at the N-terminus to red at
the C-terminus, and the secondary structure elements are labelled in accordance with previous studies.15,16 (b–e) A
comparison of the overall structure of native PBP3 (blue, orange, and red) with those of the PBP3/carbenicillin complex
(b), PBP3/ceftazidime complex (c), PBP2 of N. gonorrhoeae (d), and PBP2x from S. pneumoniae (e). This figure was
produced with PyMOL (www.pymol.org). The rest of the figures were drawn using BOBSCRIPT.22
177Native and Antibiotic-Bound P. aeruginosa PBP3showgreater structural flexibility than theC-terminal
transpeptidase domains. Thus, the superposition of
the N-terminal β subdomains (residues 50–79 and
150–221) of the PBP3/carbenicillin and PBP3/cefta-
zidime complexes with the apo-enzyme resulted in
RMSDs of 1.3 Å and 1.1 Å for 166 and 169 equivalent
Cα atoms, and 7° and 5° differences in orientation for
the head subdomains, respectively. By contrast, the
C-terminal transpeptidase domains of both acyl-
PBP3 enzymes superimpose on the apo-enzymewith
RMSDs of 0.8 Å and 0.6 Å for the carbenicillin
complex and the ceftazidime complex for 319 of 324
overlapped Cα positions. This shows that acylation
does not significantly alter the overall conformation
of the transpeptidase domain. However, significant
local changes are observed in the substrate-binding
pocketwithmovement ofβ3 relative toα2, reinstatingthe strict anti-parallel arrangement of the three β-
strands (β3, β4, and β5). Strands β3 and β4 of PBP3
bend towards the inhibitor around a hinge region
located at residue G486 on β3 and at residue L504
on β4, resulting in an approximately 4-Å movement
for the Cα atoms of K490 and A500, the last and the
first ordered residues of the β3 and β4 strands in
the apo structure, respectively (Fig. 4a). A similar
movement of the equivalent strands has been
observed following the binding of β-lactams to
other HMM5 and LMM PBPs.25 Ligand binding is
associated with an increased order of the β3–β4 and
β5–α11 loops, as shown by better electron density
for these residues in the two complexes. Both
carbenicillin and ceftazidime display well-defined
electron density in the acylated enzyme complexes
(Fig. 3b and c). The β-lactams are covalently bound
Table 2. A comparison of class B PBP structures
PDB code Number of Cα equivalences Identical sequence RMSD (Å) Rotation (Å) Translation (Å)
Overlap of the C-domain onto PBP3 native (residues 222–558)
2wad-A 267 59 1.7 NA
1rp5-A 293 75 1.9 NA
1mwr-A 262 57 2.0 NA
3equ-A 302 126 1.5 NA
Overlap of the N-terminal subdomain (residues 50–79 and 150–221)
2wad-A 84 20 1.8 24.9 1.1
1rp5-A 97 28 1.3 2.5 0.4
1mwr-A 71 24 1.4 17.0 1.0
3equ-A 90 41 1.7 8.9 0.1
Overlap of the head subdomain (residues 80–149)
2wad-A 60 8 2.5 28.7 1.0
1rp5-A 67 7 1.9 60.3 2.1
1mwr-A 60 11 2.1 76.6 0.3
3equ-A
NA, not applicable.
The structures of the C-terminal transpeptidase domain, N-terminal β-stranded subdomain, and N-terminal β-stranded head subdomain
were sequentially aligned to PBP3 using SHP.23 The results show the RMSD for Cα atoms, and the rotation and translation distances
required to overlay all of the domains. In each case, molecule A in the PDB entries for the following structures was used for the
comparison: S. pneumoniae PBP2b (PDB code 2wad), S. pneumonia PBP2x (PDB code 1rp5), S. aureus PBP2a (PDB code 1mwr), and N.
gonorrhoeae PBP2 (PDB code 3equ).
178 Native and Antibiotic-Bound P. aeruginosa PBP3to the active site S294 and adopt similar orientations
that are maintained by hydrogen-bonding inter-
actions between S485 and T487 and a carboxylate
group on both compounds (Fig. 3d and e). The
alignment of the drugs with T487 resembles a short
segment of anti-parallel β-sheet. Note that ceftazi-
dime is susceptible to hydrolysis,26 and since the R2
piperidine moiety of ceftazidime is lost on β-lactam
ring opening, both compounds have similar chem-
ical groups at this position [i.e., one methyl
(ceftazidime) or two methyls (carbenicillin)], and
these are positioned near V333 and F531 (Fig. 3g).
The principal difference between the inhibitors
involves the nature and the size of the R1 sub-
stituent (Fig. 3b and c; Supplementary Material, Fig.
S1). In both complexes, the R1 amide linkage forms
hydrogen bonds with the main-chain carbonyl of
T487 and with the side chain of N351, and a cluster
of aromatic residues (Y501, Y530, and F531) forms
hydrophobic contacts with the R1 groups (Fig. 3e
and f). In the carbenicillin complex, the R1 carboxy-
late forms hydrogen bonds with the side-chain
hydroxyl of Y409 and a water molecule, which in
turn interacts with the main-chain amide of R489.
In order to accommodate the much larger R1 sub-
stituent on ceftazidime, the side-chain of Y409 is
rotated away from the position observed in the apo-
structure. This movement creates a subpocket
where van der Waals interactions involving E291,
G293, and A488 help to position the R1 aminothia-
zole ring and allows ring-stacking interactions with
Y409. The position of the aminothiazole ring is also
stabilized through bifurcated hydrogen bonds tothe main-chain carbonyl of R489 and to the side-
chain of E291, which is the only negatively charged
residue in the cleft (Fig. 3g). The main-chain amide
of R489 donates a hydrogen bond to the thiazole
nitrogen. In the ceftazidime complex, the side-chain
of R489 is rotated towards the ligand, allowing the
side chain to donate a hydrogen bond to the R1
dimethyl/carboxylate group (Fig. 3f and g).
Conservation of active-site residues in
B. pseudomallei PBP3
As mentioned earlier, ceftazidime is used to treat
infections with B. pseudomallei. The amino acid
sequences of PBP3 from P. aeruginosa and B.
pseudomallei were aligned (accession numbers
Q51504 and Q63QJ1, respectively; data not
shown). The enzymes share an approximately 40%
identity. Of 12 residues (in and around the active
site) that are critical for P. aeruginosa PBP3
reactivity and interaction with ceftazidime (K297,
V333, S349, N351, Y409, K484, S485, T487, R489,
Y501, Y530, and F531), 9 are strictly conserved. The
differences are that V333 changes to aspartate, R489
changes to tyrosine, and Y530 changes to histidine.
These are sterically conservative changes (e.g., the
aliphatic component of the aspartate side-chain
matches closely to a part of valine) and suggest that
our model of the PBP3/ceftazidime complex
reveals the structural basis for the action of cefta-
zidime in the treatment of melioidosis. Further-
more, this model provides a template for informing
inhibitor development.
Fig. 3. The active site of PBP3. (a–c) 2Fo−Fc maps calculated after the final round of refinement and contoured at 1σ
showing the electron density for the three active site structural motifs in apo-PBP3, bound carbenicillin, and ceftazidime in
the two complexes, respectively. In (b) and (c), the carbon atoms of the acylated S294 are shown in cyan. (d–f) The active
sites of apo-PBP3, carbenicillin, and ceftazidime complexes. The protein main chains are shown as gray ribbons, side
chains are drawn as cyan sticks, and the inhibitor is shown in orange ball-and-sticks. The red spheres represent water
molecules, and the yellow broken lines represent potential hydrogen bonds. Residue V333 that makes contacts with the
bound inhibitors is not shown in (e) and (f) for clarity. (g) Comparison of the active sites of the PBP3/carbenicillin complex
(cyan) and the PBP3/ceftazidime complex (orange).
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Fig. 4. Glycerol binding, comparison with PBP1b, and electrostatic properties of the active site. (a) A diagram showing
that the glycerol binding site is separated from the inhibitor binding site by β3–β4 strands and large conformational
changes of the two strands due to inhibitor binding. The main-chain backbones of apo-PBP3 and the PBP3/carbenicillin
complex are shown as gray and blue ribbons, respectively. (b) Comparison of the glycerol-binding site in the PBP3/
carbenicillin complex with that in the apo-enzyme. The main chains and side chains are shown as ribbons and sticks,
respectively (in gray and red for apo-PBP3; in blue and cyan for the carbenicillin complex), and the glycerol molecule is
drawn as orange sticks. (c) Comparison of the active sites of the PBP3/ceftazidime complex (orange) and the S.
pneumoniae PBP1b/cefotaxime complex (cyan). (d) Electrostatic surface showing the inhibitor-binding pocket of the
PBP3/carbenicillin complex. (a) and (c) were produced with PyMOL (www.pymol.org).
180 Native and Antibiotic-Bound P. aeruginosa PBP3Active site flexibility and variations
A common feature observed in the crystal
structures of PBPs is the flexibility of the active
sites, especially the loop linking β3–β4. This may be
an intrinsic property of these enzymes that is
required for substrate binding and release during
the catalytic process. Active site flexibility has also
been suggested to be a key mechanism for acquisi-
tion of drug resistance.11 Comparison of the
structure of antibiotic-sensitive wild-type PBPswith those from resistant strains has shown that
mutations occur in residues close to but not actually
in the active site.4,11 The conformational change in
β3 and β4 strands introduced by inhibitor binding
opens up a small pocket on the other side of the β-
sheet that is occupied by water molecules in apo-
PBP3 (Fig. 4a). The crystal of the PBP3/carbenicillin
complex had been soaked with cryoprotectant
solution containing 20% glycerol prior to freezing
(no cryoprotectant was used for apo and ceftazi-
dime-soaked crystals). As a result, the pocket is
181Native and Antibiotic-Bound P. aeruginosa PBP3occupied by a well-ordered glycerol molecule,
which makes hydrogen-bonding interactions with
S248, R284, D523, and a trapped water molecule,
and hydrophobic contacts with residues G247, S248,
F290, and V521 (Fig. 4b). This pocket could be
targeted for the design of a new type of inhibitor that
restricts active site “breathing.” The influence of
such a ligand could be to increase the free energy of
PBP3 ligand binding by restricting the conforma-
tional flexibility of the enzyme.27 A potential benefit
could be use in conjunction with β-lactams to
combat drug resistance.
Apart from the three conserved active site motifs,
residues lining the substrate-binding cleft of PBPs
are poorly conserved. Amino acid insertions and
deletions often occur among PBPs and result in
variations in the shape and size of the active site
clefts. For example, S. pneumoniae PBP2x has an
extended β3–β4 loop and a shorter linker between
β5 and α11, resulting in an active-site cleft that is
wider at one end and narrower at the other end
compared to PBP3. The structure of the complex of
S. pneumoniae PBP1b with cefotaxime, a close
analogue of ceftazidime, has been reported,11
enabling a direct comparison of binding modes
with the PBP3 complex. Superimposition of the
complexes reveals that the two inhibitors dock into
their respective targets in a remarkably similar way.
The orientations of the residues that form hydrogen
bonds with the common β-lactam core of the
inhibitors, namely S485 (PBP3)/T652 (PBP1b),
T487 (PBP3)/T654 (PBP1b), and N351 (PBP3)/
N518 (PBP1b), are closely matched (Fig. 4c). N656
(PBP1b) and R489 (PBP3), which interact with the R1
groups of cefotaxime and ceftazidime, respectively,
are also closely aligned, with their relative positions
determined by the size of the R1 substituents. These
observations point to a common binding mode for
cephalosporin analogues to the HMM PBPs. Resi-
dues E291, Y409, and R489 in PBP3, which make key
interactions with the R1 groups of ceftazidime, are
replaced in PBP1b by S457, G558, and N656,
respectively, likely reducing the affinity of PBP1b
for the inhibitor given the different nature of these
residues. More generally, sequence variation at
these three positions could be a major factor
contributing to the different specificities and affin-
ities of cephalosporin analogues across PBPs.
Finally, it is striking that in all published
structures of PBP/inhibitor complexes, the inhibi-
tors occupy the central portion of the active site
pocket, leaving a large volume of the cleft unoccu-
pied (Fig. 4c and d). It may be possible to design
inhibitors that utilize these “free” volumes to
increase protein–inhibitor interactions and/or to
prevent β-lactamase hydrolysis. Such modifications
offer the potential of enhancing binding affinity for
the target and of overcoming drug resistance caused
by β-lactamase production.Experimental Procedures
Protein production
A truncated version of the ftsI gene, omitting the bases
encoding the first 34 amino acids (residues D35-G579),
was amplified by PCR using P. aeruginosa PAO1 strain
genomic DNA (ATCC strain 15692; LGC Standards Office,
UK). The template and primers were designed for ligation-
independent cloning via In-fusion™ technology (Clon-
tech). PCR with KODHiFi™ polymerase (Merck) used the
following forward and reverse primers: 5′-aagttctgttt-
cagggcccgGACCTGCACGTGATCGACC-3′ and 5′-
atggtctagaaagctttaGCCACGCCCTCCTTTTGC-3′, respec-
tively. The PCR product was purified using paramagnetic
microparticles28 (Agencourt AmPure™ System; Beckman
Coulter) and inserted into the vector pOPINF using the
protocol of Berrow et al.29 Recombinant clones were
identified by PCR with the gene-specific forward primer
and a T7 reverse primer, and verified by DNA sequencing.
Native PBP3 was produced in the E. coli strain Rosetta
pLysS (DE3) using autoinduction.30 Cells were grown in
2-L cultures of Overnight™ Express Instant TB media
(Merck) at 37 °C for 4 h, and the temperature was then
lowered to 25 °C. After incubation for a further 20 h, the
cells were harvested by centrifugation for 15 min at 6000g
and lysed using a Basic-Z Cell Disruptor (Constant
Systems) at 30,000 psi in the presence of 50 mM Tris–
HCl (pH 7.5), 500 mM NaCl, 0.2% Tween-20, 10 μg/ml
DNase, and an ethylenediaminetetraacetic-acid-free Pro-
tease Inhibitor Cocktail Tablet (Roche). The lysate was
centrifuged at 16,000g for 30 min to remove cell debris
before the soluble fraction was loaded onto a 1-ml
HisTrap FF column (GE Healthcare). The column was
washed with 50 mM Tris–HCl (pH 7.5), 500 mM NaCl,
and 20 mM imidazole before the elution of the protein in
50 mM Tris–HCl (pH 7.5), 500 mM NaCl, and 500 mM
imidazole. The protein was then injected onto a 16/60
HiLoad™ Superdex 75 column (GE Healthcare) and
eluted in 20 mM Tris–HCl (pH 7.5) and 200 mM NaCl.
Protein-containing fractions were analyzed by SDS-PAGE
(NuPage; Invitrogen) and combined, and the NaCl
concentration was adjusted to 400 mM to improve
protein solubility. Protein (4 mg/ml) was flash frozen
and stored at −80 °C.
Thermal shift assay
A thermal shift assay,31,32 using the fluorescent dye
SYPRO Orange (Invitrogen), was employed to demon-
strate that the recombinant PBP3 binds the β-lactams and
to determine their effect on protein stability. PBP3 was
screened with carbenicillin and ceftazidime. Solutions of
PBP3 at 4 μM, 1000× SYPRO Orange, and compounds at
500 μM concentration were made, and 40 μl was added to
a 96-well thin-wall PCR plate (Thermo Scientific). The
plates were sealed with adhesive PCR seal (4titude) and
heated in an Mx3005p qPCR machine (Stratagene) from
25 °C to 95 °C at a rate of 1 °C/min. Fluorescence changes
were monitored with excitation and emission wave-
lengths of 492 nm and 610 nm, respectively. Reference
wells (i.e., solutions consisting only of PBP3 and the dye)
were used to compare the melting temperature (Tm)
182 Native and Antibiotic-Bound P. aeruginosa PBP3values. In order to rule out any effects caused by the
presence of buffer, we used wells with buffer and 1000×
SYPRO Orange as controls. Experiments were carried out
in triplicate, and nonlinear regression analysis was
determined in the curve-fitting program Prism (GraphPad
Software). Tm values were calculated for each well and
compared to the reference Tm values to obtain ΔTm for
each compound. A Microsoft Excel script† was used for
convenient observations and comparison of melting
curves and thermal shifts.
Crystallization, data collection, and
structure determination
Protein crystallization was carried out using standard
Oxford Protein Production Facility protocols.33 Native
crystals were grown by sitting-drop vapor diffusion at
room temperature in 25% (wt/vol) polyethylene glycol
3350 and 0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydro-
xymethyl)propane-1,3-diol propane (pH 7.8) containing
1% (wt/vol) protamine sulfate (Silver Bullet Screen;
Hampton Research). Acyl complexes were obtained by
either cocrystallization or soaking experiments. Crystals of
the carbenicillin complex were obtained in 20% (wt/vol)
polyethylene glycol 3350 and 0.2 M disodium tartrate
containing 0.5 mM carbenicillin. The PBP3/ceftazidime
complex was obtained by soaking native crystals in the
crystallization solution containing 10 mM ceftazidime for
30 min at room temperature. All crystals were flash frozen
in liquid nitrogen and then kept at −173 °C under a stream
of nitrogen gas during data collection. No cryoprotectant
was used apart from the carbenicillin complex, where a
crystal was soaked in solution containing 20% glycerol
(vol/vol) and 80% of the reservoir solution for a few
seconds before freezing. X-ray data were collected for the
carbenicillin complex on beamline ID23.2 of the European
Synchrotron Radiation Facility (ESRF; Grenoble, France),
and data sets from the native and ceftazidime-soaked
crystals were collected on beamlines I03 and I02 of the
Diamond Light Source (Harwell, UK), respectively.
The diffraction data were indexed and integrated with
DENZO, and merged with SCALEPACK.34 The statistics
of the data are shown in Table 1. The crystals belong to the
orthorhombic space group P212121, with one protein
molecule per asymmetric unit and an approximate bulk
solvent content of 44%. The structure of the PBP3/
carbenicillin complex was solved by molecular replace-
ment using the coordinates of N. gonorrhoeae PBP2 (PDB
code 3equ)4 as search model. The starting model shares a
34% sequence identity with P. aeruginosa PBP3 and lacks
the 72 residues that form the head subdomain. The
orientation and position of the model in the PBP3 crystal
were determined using the program MOLREP35 and
refined with rigid-body refinement using data from 30 Å
to 4.0 Å. The model was then subjected to restrained
maximum-likelihood refinement with REFMAC using all
data up to 2.3 Å resolution.36 The 2Fo−Fc map calculated
at this stage showed well-defined electron density for the
transpeptidase domain, which allowed the majority of
residues within the domain to be built with confidence;
the electron density for the N-terminal domain, especially† ftp://ftp.sgc.ox.ac.uk/pub/biophysicsfor the missing head subdomain, was poor and fragmen-
ted, but gradually improved after each round of refine-
ment andmodel rebuilding with Coot.37 Several rounds of
refinement and model rebuilding led to a model of 498
residues (out of 543), with good stereochemistry and an
R-factor of 0.196 (Rfree=0.250) for all data up to 2.3 Å
resolution. The structure of the PBP3/carbenicillin com-
plex was then used to determine the structures of the apo-
enzyme and the ceftazidime complex. The statistics for the
final refined structures are given in Table 1.
Accession numbers
The atomic coordinates and structure factors for apo-
PBP3, the PBP3/carbenicillin complex, and the PBP3/
ceftazidime complex have been deposited in the PDB
under accession codes 3oc2, 3ocl, and 3ocn, respectively.
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